AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CRISPR Therapeutics AG (CRSP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

51.99

2.27 (4.57%)

At close: Feb 18, 2025, 3:59 PM

52.43

0.85%

After-hours: Feb 18, 2025, 07:57 PM EST

undefined% (undefined)

Bid	52.33
Market Cap	4.46B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.34
PE Ratio (ttm)	-11.98
Forward PE	n/a
Analyst	Buy

Ask	52.43
Volume	5,166,790
Avg. Volume (20D)	2,020,216
Open	52.05
Previous Close	49.72
Day's Range	51.02 - 55.30
52-Week Range	36.52 - 91.10
Beta	undefined

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 19, 2016

Employees 393

Stock Exchange NASDAQ

Ticker Symbol CRSP

Website https://www.crisprtx.com

Full Company Profile

Analyst Forecast

According to 20 analyst ratings, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $83, which is an increase of 59.65% from the latest price.

Buy 55.00%

Hold 40.00%

Sell 5.00%

Stock Forecasts

Next Earnings Release

CRISPR Therapeutics AG is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 days ago

+14.33%

CRISPR Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

6 days ago

+9.29%

CRISPR Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results and Barclays raised its price target on the stock from $55 to $56.

News

21 hours ago · zacks.com

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

5 days ago · seekingalpha.com

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securi...

1 week ago · fool.com

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday

On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcar...

6 days ago · zacks.com

CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

1 week ago · zacks.com

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.

1 week ago · fool.com

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equit...

1 week ago · zacks.com

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

2 weeks ago · seekingalpha.com

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Part...

2 weeks ago · seekingalpha.com

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...

2 weeks ago · zacks.com

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

Load More News